An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2016
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONODO
- 07 Jun 2017 Biomarkers information updated
- 23 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.